Medical Care
Global Painful Diabetic Neuropathy Drug Market Research Report 2025
- Mar 11, 25
- ID: 77698
- Pages: 88
- Figures: 83
- Views: 16
The global market for Painful Diabetic Neuropathy Drug was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Painful Diabetic Neuropathy Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Painful Diabetic Neuropathy Drug.
The Painful Diabetic Neuropathy Drug market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Painful Diabetic Neuropathy Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Painful Diabetic Neuropathy Drug companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Daiichi Sankyo Company, Limited
Eli Lilly and Company
Johnson & Johnson Services, Inc
Novartis AG
Pfizer Inc.
Grunenthal GmbH
ViroMed Co.
Collegium Pharmaceutical, Inc
Acorda Therapeutics, Inc
Zydus Pharmaceuticals
Mallinckrodt, Inc
Macleods Pharmaceuticals Ltd.
Lupin Pharmaceuticals
Segment by Type
Oral
Injection
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Painful Diabetic Neuropathy Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Painful Diabetic Neuropathy Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Painful Diabetic Neuropathy Drug.
The Painful Diabetic Neuropathy Drug market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Painful Diabetic Neuropathy Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Painful Diabetic Neuropathy Drug companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Daiichi Sankyo Company, Limited
Eli Lilly and Company
Johnson & Johnson Services, Inc
Novartis AG
Pfizer Inc.
Grunenthal GmbH
ViroMed Co.
Collegium Pharmaceutical, Inc
Acorda Therapeutics, Inc
Zydus Pharmaceuticals
Mallinckrodt, Inc
Macleods Pharmaceuticals Ltd.
Lupin Pharmaceuticals
Segment by Type
Oral
Injection
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Painful Diabetic Neuropathy Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Painful Diabetic Neuropathy Drug Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Oral
1.2.3 Injection
1.2.4 Others
1.3 Market by Application
1.3.1 Global Painful Diabetic Neuropathy Drug Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Painful Diabetic Neuropathy Drug Market Perspective (2020-2031)
2.2 Global Painful Diabetic Neuropathy Drug Growth Trends by Region
2.2.1 Global Painful Diabetic Neuropathy Drug Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Painful Diabetic Neuropathy Drug Historic Market Size by Region (2020-2025)
2.2.3 Painful Diabetic Neuropathy Drug Forecasted Market Size by Region (2026-2031)
2.3 Painful Diabetic Neuropathy Drug Market Dynamics
2.3.1 Painful Diabetic Neuropathy Drug Industry Trends
2.3.2 Painful Diabetic Neuropathy Drug Market Drivers
2.3.3 Painful Diabetic Neuropathy Drug Market Challenges
2.3.4 Painful Diabetic Neuropathy Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Painful Diabetic Neuropathy Drug Players by Revenue
3.1.1 Global Top Painful Diabetic Neuropathy Drug Players by Revenue (2020-2025)
3.1.2 Global Painful Diabetic Neuropathy Drug Revenue Market Share by Players (2020-2025)
3.2 Global Painful Diabetic Neuropathy Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Painful Diabetic Neuropathy Drug Revenue
3.4 Global Painful Diabetic Neuropathy Drug Market Concentration Ratio
3.4.1 Global Painful Diabetic Neuropathy Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Painful Diabetic Neuropathy Drug Revenue in 2024
3.5 Global Key Players of Painful Diabetic Neuropathy Drug Head office and Area Served
3.6 Global Key Players of Painful Diabetic Neuropathy Drug, Product and Application
3.7 Global Key Players of Painful Diabetic Neuropathy Drug, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Painful Diabetic Neuropathy Drug Breakdown Data by Type
4.1 Global Painful Diabetic Neuropathy Drug Historic Market Size by Type (2020-2025)
4.2 Global Painful Diabetic Neuropathy Drug Forecasted Market Size by Type (2026-2031)
5 Painful Diabetic Neuropathy Drug Breakdown Data by Application
5.1 Global Painful Diabetic Neuropathy Drug Historic Market Size by Application (2020-2025)
5.2 Global Painful Diabetic Neuropathy Drug Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Painful Diabetic Neuropathy Drug Market Size (2020-2031)
6.2 North America Painful Diabetic Neuropathy Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Painful Diabetic Neuropathy Drug Market Size by Country (2020-2025)
6.4 North America Painful Diabetic Neuropathy Drug Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Painful Diabetic Neuropathy Drug Market Size (2020-2031)
7.2 Europe Painful Diabetic Neuropathy Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Painful Diabetic Neuropathy Drug Market Size by Country (2020-2025)
7.4 Europe Painful Diabetic Neuropathy Drug Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Painful Diabetic Neuropathy Drug Market Size (2020-2031)
8.2 Asia-Pacific Painful Diabetic Neuropathy Drug Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Painful Diabetic Neuropathy Drug Market Size by Region (2020-2025)
8.4 Asia-Pacific Painful Diabetic Neuropathy Drug Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Painful Diabetic Neuropathy Drug Market Size (2020-2031)
9.2 Latin America Painful Diabetic Neuropathy Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Painful Diabetic Neuropathy Drug Market Size by Country (2020-2025)
9.4 Latin America Painful Diabetic Neuropathy Drug Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Painful Diabetic Neuropathy Drug Market Size (2020-2031)
10.2 Middle East & Africa Painful Diabetic Neuropathy Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Painful Diabetic Neuropathy Drug Market Size by Country (2020-2025)
10.4 Middle East & Africa Painful Diabetic Neuropathy Drug Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Daiichi Sankyo Company, Limited
11.1.1 Daiichi Sankyo Company, Limited Company Details
11.1.2 Daiichi Sankyo Company, Limited Business Overview
11.1.3 Daiichi Sankyo Company, Limited Painful Diabetic Neuropathy Drug Introduction
11.1.4 Daiichi Sankyo Company, Limited Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025)
11.1.5 Daiichi Sankyo Company, Limited Recent Development
11.2 Eli Lilly and Company
11.2.1 Eli Lilly and Company Company Details
11.2.2 Eli Lilly and Company Business Overview
11.2.3 Eli Lilly and Company Painful Diabetic Neuropathy Drug Introduction
11.2.4 Eli Lilly and Company Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025)
11.2.5 Eli Lilly and Company Recent Development
11.3 Johnson & Johnson Services, Inc
11.3.1 Johnson & Johnson Services, Inc Company Details
11.3.2 Johnson & Johnson Services, Inc Business Overview
11.3.3 Johnson & Johnson Services, Inc Painful Diabetic Neuropathy Drug Introduction
11.3.4 Johnson & Johnson Services, Inc Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025)
11.3.5 Johnson & Johnson Services, Inc Recent Development
11.4 Novartis AG
11.4.1 Novartis AG Company Details
11.4.2 Novartis AG Business Overview
11.4.3 Novartis AG Painful Diabetic Neuropathy Drug Introduction
11.4.4 Novartis AG Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025)
11.4.5 Novartis AG Recent Development
11.5 Pfizer Inc.
11.5.1 Pfizer Inc. Company Details
11.5.2 Pfizer Inc. Business Overview
11.5.3 Pfizer Inc. Painful Diabetic Neuropathy Drug Introduction
11.5.4 Pfizer Inc. Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025)
11.5.5 Pfizer Inc. Recent Development
11.6 Grunenthal GmbH
11.6.1 Grunenthal GmbH Company Details
11.6.2 Grunenthal GmbH Business Overview
11.6.3 Grunenthal GmbH Painful Diabetic Neuropathy Drug Introduction
11.6.4 Grunenthal GmbH Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025)
11.6.5 Grunenthal GmbH Recent Development
11.7 ViroMed Co.
11.7.1 ViroMed Co. Company Details
11.7.2 ViroMed Co. Business Overview
11.7.3 ViroMed Co. Painful Diabetic Neuropathy Drug Introduction
11.7.4 ViroMed Co. Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025)
11.7.5 ViroMed Co. Recent Development
11.8 Collegium Pharmaceutical, Inc
11.8.1 Collegium Pharmaceutical, Inc Company Details
11.8.2 Collegium Pharmaceutical, Inc Business Overview
11.8.3 Collegium Pharmaceutical, Inc Painful Diabetic Neuropathy Drug Introduction
11.8.4 Collegium Pharmaceutical, Inc Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025)
11.8.5 Collegium Pharmaceutical, Inc Recent Development
11.9 Acorda Therapeutics, Inc
11.9.1 Acorda Therapeutics, Inc Company Details
11.9.2 Acorda Therapeutics, Inc Business Overview
11.9.3 Acorda Therapeutics, Inc Painful Diabetic Neuropathy Drug Introduction
11.9.4 Acorda Therapeutics, Inc Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025)
11.9.5 Acorda Therapeutics, Inc Recent Development
11.10 Zydus Pharmaceuticals
11.10.1 Zydus Pharmaceuticals Company Details
11.10.2 Zydus Pharmaceuticals Business Overview
11.10.3 Zydus Pharmaceuticals Painful Diabetic Neuropathy Drug Introduction
11.10.4 Zydus Pharmaceuticals Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025)
11.10.5 Zydus Pharmaceuticals Recent Development
11.11 Mallinckrodt, Inc
11.11.1 Mallinckrodt, Inc Company Details
11.11.2 Mallinckrodt, Inc Business Overview
11.11.3 Mallinckrodt, Inc Painful Diabetic Neuropathy Drug Introduction
11.11.4 Mallinckrodt, Inc Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025)
11.11.5 Mallinckrodt, Inc Recent Development
11.12 Macleods Pharmaceuticals Ltd.
11.12.1 Macleods Pharmaceuticals Ltd. Company Details
11.12.2 Macleods Pharmaceuticals Ltd. Business Overview
11.12.3 Macleods Pharmaceuticals Ltd. Painful Diabetic Neuropathy Drug Introduction
11.12.4 Macleods Pharmaceuticals Ltd. Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025)
11.12.5 Macleods Pharmaceuticals Ltd. Recent Development
11.13 Lupin Pharmaceuticals
11.13.1 Lupin Pharmaceuticals Company Details
11.13.2 Lupin Pharmaceuticals Business Overview
11.13.3 Lupin Pharmaceuticals Painful Diabetic Neuropathy Drug Introduction
11.13.4 Lupin Pharmaceuticals Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025)
11.13.5 Lupin Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Painful Diabetic Neuropathy Drug Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Oral
1.2.3 Injection
1.2.4 Others
1.3 Market by Application
1.3.1 Global Painful Diabetic Neuropathy Drug Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Painful Diabetic Neuropathy Drug Market Perspective (2020-2031)
2.2 Global Painful Diabetic Neuropathy Drug Growth Trends by Region
2.2.1 Global Painful Diabetic Neuropathy Drug Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Painful Diabetic Neuropathy Drug Historic Market Size by Region (2020-2025)
2.2.3 Painful Diabetic Neuropathy Drug Forecasted Market Size by Region (2026-2031)
2.3 Painful Diabetic Neuropathy Drug Market Dynamics
2.3.1 Painful Diabetic Neuropathy Drug Industry Trends
2.3.2 Painful Diabetic Neuropathy Drug Market Drivers
2.3.3 Painful Diabetic Neuropathy Drug Market Challenges
2.3.4 Painful Diabetic Neuropathy Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Painful Diabetic Neuropathy Drug Players by Revenue
3.1.1 Global Top Painful Diabetic Neuropathy Drug Players by Revenue (2020-2025)
3.1.2 Global Painful Diabetic Neuropathy Drug Revenue Market Share by Players (2020-2025)
3.2 Global Painful Diabetic Neuropathy Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Painful Diabetic Neuropathy Drug Revenue
3.4 Global Painful Diabetic Neuropathy Drug Market Concentration Ratio
3.4.1 Global Painful Diabetic Neuropathy Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Painful Diabetic Neuropathy Drug Revenue in 2024
3.5 Global Key Players of Painful Diabetic Neuropathy Drug Head office and Area Served
3.6 Global Key Players of Painful Diabetic Neuropathy Drug, Product and Application
3.7 Global Key Players of Painful Diabetic Neuropathy Drug, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Painful Diabetic Neuropathy Drug Breakdown Data by Type
4.1 Global Painful Diabetic Neuropathy Drug Historic Market Size by Type (2020-2025)
4.2 Global Painful Diabetic Neuropathy Drug Forecasted Market Size by Type (2026-2031)
5 Painful Diabetic Neuropathy Drug Breakdown Data by Application
5.1 Global Painful Diabetic Neuropathy Drug Historic Market Size by Application (2020-2025)
5.2 Global Painful Diabetic Neuropathy Drug Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Painful Diabetic Neuropathy Drug Market Size (2020-2031)
6.2 North America Painful Diabetic Neuropathy Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Painful Diabetic Neuropathy Drug Market Size by Country (2020-2025)
6.4 North America Painful Diabetic Neuropathy Drug Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Painful Diabetic Neuropathy Drug Market Size (2020-2031)
7.2 Europe Painful Diabetic Neuropathy Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Painful Diabetic Neuropathy Drug Market Size by Country (2020-2025)
7.4 Europe Painful Diabetic Neuropathy Drug Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Painful Diabetic Neuropathy Drug Market Size (2020-2031)
8.2 Asia-Pacific Painful Diabetic Neuropathy Drug Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Painful Diabetic Neuropathy Drug Market Size by Region (2020-2025)
8.4 Asia-Pacific Painful Diabetic Neuropathy Drug Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Painful Diabetic Neuropathy Drug Market Size (2020-2031)
9.2 Latin America Painful Diabetic Neuropathy Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Painful Diabetic Neuropathy Drug Market Size by Country (2020-2025)
9.4 Latin America Painful Diabetic Neuropathy Drug Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Painful Diabetic Neuropathy Drug Market Size (2020-2031)
10.2 Middle East & Africa Painful Diabetic Neuropathy Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Painful Diabetic Neuropathy Drug Market Size by Country (2020-2025)
10.4 Middle East & Africa Painful Diabetic Neuropathy Drug Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Daiichi Sankyo Company, Limited
11.1.1 Daiichi Sankyo Company, Limited Company Details
11.1.2 Daiichi Sankyo Company, Limited Business Overview
11.1.3 Daiichi Sankyo Company, Limited Painful Diabetic Neuropathy Drug Introduction
11.1.4 Daiichi Sankyo Company, Limited Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025)
11.1.5 Daiichi Sankyo Company, Limited Recent Development
11.2 Eli Lilly and Company
11.2.1 Eli Lilly and Company Company Details
11.2.2 Eli Lilly and Company Business Overview
11.2.3 Eli Lilly and Company Painful Diabetic Neuropathy Drug Introduction
11.2.4 Eli Lilly and Company Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025)
11.2.5 Eli Lilly and Company Recent Development
11.3 Johnson & Johnson Services, Inc
11.3.1 Johnson & Johnson Services, Inc Company Details
11.3.2 Johnson & Johnson Services, Inc Business Overview
11.3.3 Johnson & Johnson Services, Inc Painful Diabetic Neuropathy Drug Introduction
11.3.4 Johnson & Johnson Services, Inc Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025)
11.3.5 Johnson & Johnson Services, Inc Recent Development
11.4 Novartis AG
11.4.1 Novartis AG Company Details
11.4.2 Novartis AG Business Overview
11.4.3 Novartis AG Painful Diabetic Neuropathy Drug Introduction
11.4.4 Novartis AG Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025)
11.4.5 Novartis AG Recent Development
11.5 Pfizer Inc.
11.5.1 Pfizer Inc. Company Details
11.5.2 Pfizer Inc. Business Overview
11.5.3 Pfizer Inc. Painful Diabetic Neuropathy Drug Introduction
11.5.4 Pfizer Inc. Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025)
11.5.5 Pfizer Inc. Recent Development
11.6 Grunenthal GmbH
11.6.1 Grunenthal GmbH Company Details
11.6.2 Grunenthal GmbH Business Overview
11.6.3 Grunenthal GmbH Painful Diabetic Neuropathy Drug Introduction
11.6.4 Grunenthal GmbH Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025)
11.6.5 Grunenthal GmbH Recent Development
11.7 ViroMed Co.
11.7.1 ViroMed Co. Company Details
11.7.2 ViroMed Co. Business Overview
11.7.3 ViroMed Co. Painful Diabetic Neuropathy Drug Introduction
11.7.4 ViroMed Co. Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025)
11.7.5 ViroMed Co. Recent Development
11.8 Collegium Pharmaceutical, Inc
11.8.1 Collegium Pharmaceutical, Inc Company Details
11.8.2 Collegium Pharmaceutical, Inc Business Overview
11.8.3 Collegium Pharmaceutical, Inc Painful Diabetic Neuropathy Drug Introduction
11.8.4 Collegium Pharmaceutical, Inc Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025)
11.8.5 Collegium Pharmaceutical, Inc Recent Development
11.9 Acorda Therapeutics, Inc
11.9.1 Acorda Therapeutics, Inc Company Details
11.9.2 Acorda Therapeutics, Inc Business Overview
11.9.3 Acorda Therapeutics, Inc Painful Diabetic Neuropathy Drug Introduction
11.9.4 Acorda Therapeutics, Inc Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025)
11.9.5 Acorda Therapeutics, Inc Recent Development
11.10 Zydus Pharmaceuticals
11.10.1 Zydus Pharmaceuticals Company Details
11.10.2 Zydus Pharmaceuticals Business Overview
11.10.3 Zydus Pharmaceuticals Painful Diabetic Neuropathy Drug Introduction
11.10.4 Zydus Pharmaceuticals Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025)
11.10.5 Zydus Pharmaceuticals Recent Development
11.11 Mallinckrodt, Inc
11.11.1 Mallinckrodt, Inc Company Details
11.11.2 Mallinckrodt, Inc Business Overview
11.11.3 Mallinckrodt, Inc Painful Diabetic Neuropathy Drug Introduction
11.11.4 Mallinckrodt, Inc Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025)
11.11.5 Mallinckrodt, Inc Recent Development
11.12 Macleods Pharmaceuticals Ltd.
11.12.1 Macleods Pharmaceuticals Ltd. Company Details
11.12.2 Macleods Pharmaceuticals Ltd. Business Overview
11.12.3 Macleods Pharmaceuticals Ltd. Painful Diabetic Neuropathy Drug Introduction
11.12.4 Macleods Pharmaceuticals Ltd. Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025)
11.12.5 Macleods Pharmaceuticals Ltd. Recent Development
11.13 Lupin Pharmaceuticals
11.13.1 Lupin Pharmaceuticals Company Details
11.13.2 Lupin Pharmaceuticals Business Overview
11.13.3 Lupin Pharmaceuticals Painful Diabetic Neuropathy Drug Introduction
11.13.4 Lupin Pharmaceuticals Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025)
11.13.5 Lupin Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Painful Diabetic Neuropathy Drug Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Oral
Table 3. Key Players of Injection
Table 4. Key Players of Others
Table 5. Global Painful Diabetic Neuropathy Drug Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Painful Diabetic Neuropathy Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Painful Diabetic Neuropathy Drug Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global Painful Diabetic Neuropathy Drug Market Share by Region (2020-2025)
Table 9. Global Painful Diabetic Neuropathy Drug Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global Painful Diabetic Neuropathy Drug Market Share by Region (2026-2031)
Table 11. Painful Diabetic Neuropathy Drug Market Trends
Table 12. Painful Diabetic Neuropathy Drug Market Drivers
Table 13. Painful Diabetic Neuropathy Drug Market Challenges
Table 14. Painful Diabetic Neuropathy Drug Market Restraints
Table 15. Global Painful Diabetic Neuropathy Drug Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global Painful Diabetic Neuropathy Drug Market Share by Players (2020-2025)
Table 17. Global Top Painful Diabetic Neuropathy Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Painful Diabetic Neuropathy Drug as of 2024)
Table 18. Ranking of Global Top Painful Diabetic Neuropathy Drug Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by Painful Diabetic Neuropathy Drug Revenue (CR5 and HHI) & (2020-2025)
Table 20. Global Key Players of Painful Diabetic Neuropathy Drug, Headquarters and Area Served
Table 21. Global Key Players of Painful Diabetic Neuropathy Drug, Product and Application
Table 22. Global Key Players of Painful Diabetic Neuropathy Drug, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Painful Diabetic Neuropathy Drug Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global Painful Diabetic Neuropathy Drug Revenue Market Share by Type (2020-2025)
Table 26. Global Painful Diabetic Neuropathy Drug Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global Painful Diabetic Neuropathy Drug Revenue Market Share by Type (2026-2031)
Table 28. Global Painful Diabetic Neuropathy Drug Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global Painful Diabetic Neuropathy Drug Revenue Market Share by Application (2020-2025)
Table 30. Global Painful Diabetic Neuropathy Drug Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global Painful Diabetic Neuropathy Drug Revenue Market Share by Application (2026-2031)
Table 32. North America Painful Diabetic Neuropathy Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America Painful Diabetic Neuropathy Drug Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America Painful Diabetic Neuropathy Drug Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe Painful Diabetic Neuropathy Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe Painful Diabetic Neuropathy Drug Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe Painful Diabetic Neuropathy Drug Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific Painful Diabetic Neuropathy Drug Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific Painful Diabetic Neuropathy Drug Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific Painful Diabetic Neuropathy Drug Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America Painful Diabetic Neuropathy Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America Painful Diabetic Neuropathy Drug Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America Painful Diabetic Neuropathy Drug Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa Painful Diabetic Neuropathy Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa Painful Diabetic Neuropathy Drug Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Painful Diabetic Neuropathy Drug Market Size by Country (2026-2031) & (US$ Million)
Table 47. Daiichi Sankyo Company, Limited Company Details
Table 48. Daiichi Sankyo Company, Limited Business Overview
Table 49. Daiichi Sankyo Company, Limited Painful Diabetic Neuropathy Drug Product
Table 50. Daiichi Sankyo Company, Limited Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025) & (US$ Million)
Table 51. Daiichi Sankyo Company, Limited Recent Development
Table 52. Eli Lilly and Company Company Details
Table 53. Eli Lilly and Company Business Overview
Table 54. Eli Lilly and Company Painful Diabetic Neuropathy Drug Product
Table 55. Eli Lilly and Company Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025) & (US$ Million)
Table 56. Eli Lilly and Company Recent Development
Table 57. Johnson & Johnson Services, Inc Company Details
Table 58. Johnson & Johnson Services, Inc Business Overview
Table 59. Johnson & Johnson Services, Inc Painful Diabetic Neuropathy Drug Product
Table 60. Johnson & Johnson Services, Inc Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025) & (US$ Million)
Table 61. Johnson & Johnson Services, Inc Recent Development
Table 62. Novartis AG Company Details
Table 63. Novartis AG Business Overview
Table 64. Novartis AG Painful Diabetic Neuropathy Drug Product
Table 65. Novartis AG Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025) & (US$ Million)
Table 66. Novartis AG Recent Development
Table 67. Pfizer Inc. Company Details
Table 68. Pfizer Inc. Business Overview
Table 69. Pfizer Inc. Painful Diabetic Neuropathy Drug Product
Table 70. Pfizer Inc. Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025) & (US$ Million)
Table 71. Pfizer Inc. Recent Development
Table 72. Grunenthal GmbH Company Details
Table 73. Grunenthal GmbH Business Overview
Table 74. Grunenthal GmbH Painful Diabetic Neuropathy Drug Product
Table 75. Grunenthal GmbH Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025) & (US$ Million)
Table 76. Grunenthal GmbH Recent Development
Table 77. ViroMed Co. Company Details
Table 78. ViroMed Co. Business Overview
Table 79. ViroMed Co. Painful Diabetic Neuropathy Drug Product
Table 80. ViroMed Co. Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025) & (US$ Million)
Table 81. ViroMed Co. Recent Development
Table 82. Collegium Pharmaceutical, Inc Company Details
Table 83. Collegium Pharmaceutical, Inc Business Overview
Table 84. Collegium Pharmaceutical, Inc Painful Diabetic Neuropathy Drug Product
Table 85. Collegium Pharmaceutical, Inc Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025) & (US$ Million)
Table 86. Collegium Pharmaceutical, Inc Recent Development
Table 87. Acorda Therapeutics, Inc Company Details
Table 88. Acorda Therapeutics, Inc Business Overview
Table 89. Acorda Therapeutics, Inc Painful Diabetic Neuropathy Drug Product
Table 90. Acorda Therapeutics, Inc Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025) & (US$ Million)
Table 91. Acorda Therapeutics, Inc Recent Development
Table 92. Zydus Pharmaceuticals Company Details
Table 93. Zydus Pharmaceuticals Business Overview
Table 94. Zydus Pharmaceuticals Painful Diabetic Neuropathy Drug Product
Table 95. Zydus Pharmaceuticals Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025) & (US$ Million)
Table 96. Zydus Pharmaceuticals Recent Development
Table 97. Mallinckrodt, Inc Company Details
Table 98. Mallinckrodt, Inc Business Overview
Table 99. Mallinckrodt, Inc Painful Diabetic Neuropathy Drug Product
Table 100. Mallinckrodt, Inc Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025) & (US$ Million)
Table 101. Mallinckrodt, Inc Recent Development
Table 102. Macleods Pharmaceuticals Ltd. Company Details
Table 103. Macleods Pharmaceuticals Ltd. Business Overview
Table 104. Macleods Pharmaceuticals Ltd. Painful Diabetic Neuropathy Drug Product
Table 105. Macleods Pharmaceuticals Ltd. Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025) & (US$ Million)
Table 106. Macleods Pharmaceuticals Ltd. Recent Development
Table 107. Lupin Pharmaceuticals Company Details
Table 108. Lupin Pharmaceuticals Business Overview
Table 109. Lupin Pharmaceuticals Painful Diabetic Neuropathy Drug Product
Table 110. Lupin Pharmaceuticals Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025) & (US$ Million)
Table 111. Lupin Pharmaceuticals Recent Development
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
Table 115. Authors List of This Report
List of Figures
Figure 1. Painful Diabetic Neuropathy Drug Picture
Figure 2. Global Painful Diabetic Neuropathy Drug Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Painful Diabetic Neuropathy Drug Market Share by Type: 2024 VS 2031
Figure 4. Oral Features
Figure 5. Injection Features
Figure 6. Others Features
Figure 7. Global Painful Diabetic Neuropathy Drug Market Size by Application (2020-2031) & (US$ Million)
Figure 8. Global Painful Diabetic Neuropathy Drug Market Share by Application: 2024 VS 2031
Figure 9. Hospital Case Studies
Figure 10. Clinic Case Studies
Figure 11. Others Case Studies
Figure 12. Painful Diabetic Neuropathy Drug Report Years Considered
Figure 13. Global Painful Diabetic Neuropathy Drug Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 14. Global Painful Diabetic Neuropathy Drug Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Painful Diabetic Neuropathy Drug Market Share by Region: 2024 VS 2031
Figure 16. Global Painful Diabetic Neuropathy Drug Market Share by Players in 2024
Figure 17. Global Top Painful Diabetic Neuropathy Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Painful Diabetic Neuropathy Drug as of 2024)
Figure 18. The Top 10 and 5 Players Market Share by Painful Diabetic Neuropathy Drug Revenue in 2024
Figure 19. North America Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. North America Painful Diabetic Neuropathy Drug Market Share by Country (2020-2031)
Figure 21. United States Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Canada Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Painful Diabetic Neuropathy Drug Market Share by Country (2020-2031)
Figure 25. Germany Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. France Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. U.K. Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Italy Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Russia Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Nordic Countries Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Painful Diabetic Neuropathy Drug Market Share by Region (2020-2031)
Figure 33. China Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Japan Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. South Korea Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Southeast Asia Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. India Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Australia Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Painful Diabetic Neuropathy Drug Market Share by Country (2020-2031)
Figure 41. Mexico Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Brazil Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Painful Diabetic Neuropathy Drug Market Share by Country (2020-2031)
Figure 45. Turkey Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Saudi Arabia Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. UAE Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Daiichi Sankyo Company, Limited Revenue Growth Rate in Painful Diabetic Neuropathy Drug Business (2020-2025)
Figure 49. Eli Lilly and Company Revenue Growth Rate in Painful Diabetic Neuropathy Drug Business (2020-2025)
Figure 50. Johnson & Johnson Services, Inc Revenue Growth Rate in Painful Diabetic Neuropathy Drug Business (2020-2025)
Figure 51. Novartis AG Revenue Growth Rate in Painful Diabetic Neuropathy Drug Business (2020-2025)
Figure 52. Pfizer Inc. Revenue Growth Rate in Painful Diabetic Neuropathy Drug Business (2020-2025)
Figure 53. Grunenthal GmbH Revenue Growth Rate in Painful Diabetic Neuropathy Drug Business (2020-2025)
Figure 54. ViroMed Co. Revenue Growth Rate in Painful Diabetic Neuropathy Drug Business (2020-2025)
Figure 55. Collegium Pharmaceutical, Inc Revenue Growth Rate in Painful Diabetic Neuropathy Drug Business (2020-2025)
Figure 56. Acorda Therapeutics, Inc Revenue Growth Rate in Painful Diabetic Neuropathy Drug Business (2020-2025)
Figure 57. Zydus Pharmaceuticals Revenue Growth Rate in Painful Diabetic Neuropathy Drug Business (2020-2025)
Figure 58. Mallinckrodt, Inc Revenue Growth Rate in Painful Diabetic Neuropathy Drug Business (2020-2025)
Figure 59. Macleods Pharmaceuticals Ltd. Revenue Growth Rate in Painful Diabetic Neuropathy Drug Business (2020-2025)
Figure 60. Lupin Pharmaceuticals Revenue Growth Rate in Painful Diabetic Neuropathy Drug Business (2020-2025)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Table 1. Global Painful Diabetic Neuropathy Drug Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Oral
Table 3. Key Players of Injection
Table 4. Key Players of Others
Table 5. Global Painful Diabetic Neuropathy Drug Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Painful Diabetic Neuropathy Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Painful Diabetic Neuropathy Drug Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global Painful Diabetic Neuropathy Drug Market Share by Region (2020-2025)
Table 9. Global Painful Diabetic Neuropathy Drug Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global Painful Diabetic Neuropathy Drug Market Share by Region (2026-2031)
Table 11. Painful Diabetic Neuropathy Drug Market Trends
Table 12. Painful Diabetic Neuropathy Drug Market Drivers
Table 13. Painful Diabetic Neuropathy Drug Market Challenges
Table 14. Painful Diabetic Neuropathy Drug Market Restraints
Table 15. Global Painful Diabetic Neuropathy Drug Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global Painful Diabetic Neuropathy Drug Market Share by Players (2020-2025)
Table 17. Global Top Painful Diabetic Neuropathy Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Painful Diabetic Neuropathy Drug as of 2024)
Table 18. Ranking of Global Top Painful Diabetic Neuropathy Drug Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by Painful Diabetic Neuropathy Drug Revenue (CR5 and HHI) & (2020-2025)
Table 20. Global Key Players of Painful Diabetic Neuropathy Drug, Headquarters and Area Served
Table 21. Global Key Players of Painful Diabetic Neuropathy Drug, Product and Application
Table 22. Global Key Players of Painful Diabetic Neuropathy Drug, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Painful Diabetic Neuropathy Drug Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global Painful Diabetic Neuropathy Drug Revenue Market Share by Type (2020-2025)
Table 26. Global Painful Diabetic Neuropathy Drug Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global Painful Diabetic Neuropathy Drug Revenue Market Share by Type (2026-2031)
Table 28. Global Painful Diabetic Neuropathy Drug Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global Painful Diabetic Neuropathy Drug Revenue Market Share by Application (2020-2025)
Table 30. Global Painful Diabetic Neuropathy Drug Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global Painful Diabetic Neuropathy Drug Revenue Market Share by Application (2026-2031)
Table 32. North America Painful Diabetic Neuropathy Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America Painful Diabetic Neuropathy Drug Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America Painful Diabetic Neuropathy Drug Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe Painful Diabetic Neuropathy Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe Painful Diabetic Neuropathy Drug Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe Painful Diabetic Neuropathy Drug Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific Painful Diabetic Neuropathy Drug Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific Painful Diabetic Neuropathy Drug Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific Painful Diabetic Neuropathy Drug Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America Painful Diabetic Neuropathy Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America Painful Diabetic Neuropathy Drug Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America Painful Diabetic Neuropathy Drug Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa Painful Diabetic Neuropathy Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa Painful Diabetic Neuropathy Drug Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Painful Diabetic Neuropathy Drug Market Size by Country (2026-2031) & (US$ Million)
Table 47. Daiichi Sankyo Company, Limited Company Details
Table 48. Daiichi Sankyo Company, Limited Business Overview
Table 49. Daiichi Sankyo Company, Limited Painful Diabetic Neuropathy Drug Product
Table 50. Daiichi Sankyo Company, Limited Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025) & (US$ Million)
Table 51. Daiichi Sankyo Company, Limited Recent Development
Table 52. Eli Lilly and Company Company Details
Table 53. Eli Lilly and Company Business Overview
Table 54. Eli Lilly and Company Painful Diabetic Neuropathy Drug Product
Table 55. Eli Lilly and Company Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025) & (US$ Million)
Table 56. Eli Lilly and Company Recent Development
Table 57. Johnson & Johnson Services, Inc Company Details
Table 58. Johnson & Johnson Services, Inc Business Overview
Table 59. Johnson & Johnson Services, Inc Painful Diabetic Neuropathy Drug Product
Table 60. Johnson & Johnson Services, Inc Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025) & (US$ Million)
Table 61. Johnson & Johnson Services, Inc Recent Development
Table 62. Novartis AG Company Details
Table 63. Novartis AG Business Overview
Table 64. Novartis AG Painful Diabetic Neuropathy Drug Product
Table 65. Novartis AG Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025) & (US$ Million)
Table 66. Novartis AG Recent Development
Table 67. Pfizer Inc. Company Details
Table 68. Pfizer Inc. Business Overview
Table 69. Pfizer Inc. Painful Diabetic Neuropathy Drug Product
Table 70. Pfizer Inc. Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025) & (US$ Million)
Table 71. Pfizer Inc. Recent Development
Table 72. Grunenthal GmbH Company Details
Table 73. Grunenthal GmbH Business Overview
Table 74. Grunenthal GmbH Painful Diabetic Neuropathy Drug Product
Table 75. Grunenthal GmbH Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025) & (US$ Million)
Table 76. Grunenthal GmbH Recent Development
Table 77. ViroMed Co. Company Details
Table 78. ViroMed Co. Business Overview
Table 79. ViroMed Co. Painful Diabetic Neuropathy Drug Product
Table 80. ViroMed Co. Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025) & (US$ Million)
Table 81. ViroMed Co. Recent Development
Table 82. Collegium Pharmaceutical, Inc Company Details
Table 83. Collegium Pharmaceutical, Inc Business Overview
Table 84. Collegium Pharmaceutical, Inc Painful Diabetic Neuropathy Drug Product
Table 85. Collegium Pharmaceutical, Inc Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025) & (US$ Million)
Table 86. Collegium Pharmaceutical, Inc Recent Development
Table 87. Acorda Therapeutics, Inc Company Details
Table 88. Acorda Therapeutics, Inc Business Overview
Table 89. Acorda Therapeutics, Inc Painful Diabetic Neuropathy Drug Product
Table 90. Acorda Therapeutics, Inc Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025) & (US$ Million)
Table 91. Acorda Therapeutics, Inc Recent Development
Table 92. Zydus Pharmaceuticals Company Details
Table 93. Zydus Pharmaceuticals Business Overview
Table 94. Zydus Pharmaceuticals Painful Diabetic Neuropathy Drug Product
Table 95. Zydus Pharmaceuticals Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025) & (US$ Million)
Table 96. Zydus Pharmaceuticals Recent Development
Table 97. Mallinckrodt, Inc Company Details
Table 98. Mallinckrodt, Inc Business Overview
Table 99. Mallinckrodt, Inc Painful Diabetic Neuropathy Drug Product
Table 100. Mallinckrodt, Inc Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025) & (US$ Million)
Table 101. Mallinckrodt, Inc Recent Development
Table 102. Macleods Pharmaceuticals Ltd. Company Details
Table 103. Macleods Pharmaceuticals Ltd. Business Overview
Table 104. Macleods Pharmaceuticals Ltd. Painful Diabetic Neuropathy Drug Product
Table 105. Macleods Pharmaceuticals Ltd. Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025) & (US$ Million)
Table 106. Macleods Pharmaceuticals Ltd. Recent Development
Table 107. Lupin Pharmaceuticals Company Details
Table 108. Lupin Pharmaceuticals Business Overview
Table 109. Lupin Pharmaceuticals Painful Diabetic Neuropathy Drug Product
Table 110. Lupin Pharmaceuticals Revenue in Painful Diabetic Neuropathy Drug Business (2020-2025) & (US$ Million)
Table 111. Lupin Pharmaceuticals Recent Development
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
Table 115. Authors List of This Report
List of Figures
Figure 1. Painful Diabetic Neuropathy Drug Picture
Figure 2. Global Painful Diabetic Neuropathy Drug Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Painful Diabetic Neuropathy Drug Market Share by Type: 2024 VS 2031
Figure 4. Oral Features
Figure 5. Injection Features
Figure 6. Others Features
Figure 7. Global Painful Diabetic Neuropathy Drug Market Size by Application (2020-2031) & (US$ Million)
Figure 8. Global Painful Diabetic Neuropathy Drug Market Share by Application: 2024 VS 2031
Figure 9. Hospital Case Studies
Figure 10. Clinic Case Studies
Figure 11. Others Case Studies
Figure 12. Painful Diabetic Neuropathy Drug Report Years Considered
Figure 13. Global Painful Diabetic Neuropathy Drug Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 14. Global Painful Diabetic Neuropathy Drug Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Painful Diabetic Neuropathy Drug Market Share by Region: 2024 VS 2031
Figure 16. Global Painful Diabetic Neuropathy Drug Market Share by Players in 2024
Figure 17. Global Top Painful Diabetic Neuropathy Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Painful Diabetic Neuropathy Drug as of 2024)
Figure 18. The Top 10 and 5 Players Market Share by Painful Diabetic Neuropathy Drug Revenue in 2024
Figure 19. North America Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. North America Painful Diabetic Neuropathy Drug Market Share by Country (2020-2031)
Figure 21. United States Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Canada Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Painful Diabetic Neuropathy Drug Market Share by Country (2020-2031)
Figure 25. Germany Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. France Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. U.K. Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Italy Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Russia Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Nordic Countries Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Painful Diabetic Neuropathy Drug Market Share by Region (2020-2031)
Figure 33. China Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Japan Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. South Korea Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Southeast Asia Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. India Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Australia Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Painful Diabetic Neuropathy Drug Market Share by Country (2020-2031)
Figure 41. Mexico Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Brazil Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Painful Diabetic Neuropathy Drug Market Share by Country (2020-2031)
Figure 45. Turkey Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Saudi Arabia Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. UAE Painful Diabetic Neuropathy Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Daiichi Sankyo Company, Limited Revenue Growth Rate in Painful Diabetic Neuropathy Drug Business (2020-2025)
Figure 49. Eli Lilly and Company Revenue Growth Rate in Painful Diabetic Neuropathy Drug Business (2020-2025)
Figure 50. Johnson & Johnson Services, Inc Revenue Growth Rate in Painful Diabetic Neuropathy Drug Business (2020-2025)
Figure 51. Novartis AG Revenue Growth Rate in Painful Diabetic Neuropathy Drug Business (2020-2025)
Figure 52. Pfizer Inc. Revenue Growth Rate in Painful Diabetic Neuropathy Drug Business (2020-2025)
Figure 53. Grunenthal GmbH Revenue Growth Rate in Painful Diabetic Neuropathy Drug Business (2020-2025)
Figure 54. ViroMed Co. Revenue Growth Rate in Painful Diabetic Neuropathy Drug Business (2020-2025)
Figure 55. Collegium Pharmaceutical, Inc Revenue Growth Rate in Painful Diabetic Neuropathy Drug Business (2020-2025)
Figure 56. Acorda Therapeutics, Inc Revenue Growth Rate in Painful Diabetic Neuropathy Drug Business (2020-2025)
Figure 57. Zydus Pharmaceuticals Revenue Growth Rate in Painful Diabetic Neuropathy Drug Business (2020-2025)
Figure 58. Mallinckrodt, Inc Revenue Growth Rate in Painful Diabetic Neuropathy Drug Business (2020-2025)
Figure 59. Macleods Pharmaceuticals Ltd. Revenue Growth Rate in Painful Diabetic Neuropathy Drug Business (2020-2025)
Figure 60. Lupin Pharmaceuticals Revenue Growth Rate in Painful Diabetic Neuropathy Drug Business (2020-2025)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Household Embroidery Machines Market Research Report 2025
Jul 18, 25
Global Residential Electric Underfloor Heating Market Research Report 2025
Jul 18, 25
Global Commercial Electric Underfloor Heating Market Research Report 2025
Jul 18, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232